Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading Volume

Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw unusually-high trading volume on Friday . Approximately 471,292 shares were traded during mid-day trading, an increase of 114% from the previous session’s volume of 219,724 shares.The stock last traded at $16.88 and had previously closed at $17.67.

Analysts Set New Price Targets

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

Enliven Therapeutics Stock Performance

The firm has a market capitalization of $808.79 million, a PE ratio of -7.89 and a beta of 1.06. The business’s 50 day moving average is $17.05 and its two-hundred day moving average is $14.36.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now directly owns 771,983 shares of the company’s stock, valued at $11,579,745. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $15.69, for a total value of $188,280.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the completion of the transaction, the insider now owns 771,983 shares in the company, valued at approximately $11,579,745. The disclosure for this sale can be found here. In the last ninety days, insiders sold 763,661 shares of company stock valued at $13,213,762. Insiders own 45.80% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the company. AJOVista LLC purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at about $28,000. Tower Research Capital LLC TRC purchased a new position in shares of Enliven Therapeutics in the first quarter valued at about $36,000. Ameritas Investment Partners Inc. purchased a new position in shares of Enliven Therapeutics in the second quarter valued at about $39,000. Royal Bank of Canada increased its position in shares of Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock valued at $63,000 after acquiring an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $66,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.